VANGL2 and melanoma: In melanoma, RNF43 has been found to inhibit cell invasion and reverse the resistance to BRAF V600E and MEK inhibitors by stimulating the ubiquitination and proteasomal degradation of VANGL2 and inhibiting ROR2 in vitro and in vivo [58].